$BDRX Up 50% Premarket! 🚀 🔹 Biodexa Pharmaceuticals catching major momentum as traders revisit its FDA Fast Track designation for eRapa in familial adenomatou

$BDRX Up 50% Premarket! 🚀 🔹 Biodexa Pharmaceuticals catching major momentum as traders revisit its FDA Fast Track designation for eRapa in familial adenomatous polyposis 📈 🔹 Clinical-stage biotech focused on rare cancers + serious diseases with programs across FAP, brain cancers, bladder cancer …